Smithers Pharmaceutical Development Services supports the development of large-molecule therapeutics from discovery through phase IV. As a GLP, GCP and CLIA certified lab, we have the ability to develop and validate ligand-binding and cell-based assays for any indication with instrumentation that can reach sensitivities into the femtogram range for more thorough PK/TK and PD assessment.

Services include PK/TK , PD, ADA and NAB assay development, validation and sample analysis, biomarker discovery and discovery bioassay among many other services.

Smithers Pharmaceutical Development Services is currently supporting the bioanalytical development of biologics, mono/polyclonal antibodies, bi-/multi-specific antibodies, CAR-T/TCR and regenerative medicine, biosimilar/-betters, ADC’s, peptides, gene-therapy as well as nucleotide-based therapeutics in addition to vaccines on a wide array of ligand-binding assay platforms.